RelB, a good prognosis predictor, links cell-cycle and migration to glioma tumorigenesis
- Feng Shen
- Qing Guo
- Qi Hu
- Ailiang Zeng
- Weining Wu
- Wei Yan
- Yongping You
Published online on: January 29, 2018
Copyright: © Shen et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
Nuclear factor κB (NF‑κB) exhibits an important role in inflammation and tumorigenesis. The key regulatory protein of the pathway, RELB Proto‑Oncogene, NF‑KB Subunit (relB), is overexpressed and associated with the pathogenesis of a variety of malignant tumors. However, the molecular features and clinical signature of relB expression in gliomas remains to be elucidated. The present study obtained the raw sequencing data of 325 glioma samples of all grades from the Chinese Glioma Genome Atlas (CGGA) database and human glioma cell line (LN229) from the Chinese Academy of Sciences cell bank. Cell proliferation, invasion and wound healing assays were used for functional annotation of relB. Western blot analysis was used for validating the protein expression of relB, matrix metalloproteinase (MMP)‑2 and MMP‑9 in a further 77 glioma samples. In Diffuse Glioma data, relB expression was associated with glioma grade, demonstrated a mesenchymal subtype preference and cell development association. The downregulation of relB expression inhibited glioma cell migration and invasion by regulating the MMPs in vitro. relB expression was independently associated with grade and prognosis of grade III and grade IV gliomas, suggesting that relB is a novel biomarker with therapeutic potential for predicting prognosis in glioma.